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Autoimmune encephalitis is associated with a wide variety of antibodies and clinical 
 presentations. Voltage-gated potassium channel (VGKC) antibodies are a cause of 
 autoimmune non-paraneoplastic encephalitis characterized by memory impairment, 
psychiatric symptoms, and seizures. We present a case of VGKC encephalitis likely pre-
ceding an ischemic stroke. Reports of autoimmune encephalitis associated with ischemic 
stroke are rare. Several hypotheses linking these two disease processes are proposed.
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INtRoDUCtIoN
Autoimmune encephalitis is associated with a wide variety of antibodies and clinical presenta-
tions. Voltage-gated potassium channel (VGKC) antibodies are a cause of autoimmune encepha-
litis that is not typically associated with an underlying tumor. The disorder is characterized by 
memory impairment, psychiatric symptoms, and seizures (1). More recent research has identified 
several antibodies responsible for the VGKC spectrum of diseases. Currently, there are three main 
categories: leucine-rich glioma inactivated-1 (LGI1), contactin-associated protein (Caspr2), and 
VGKC with unknown antigen. LGI1 is associated with the classic limbic encephalitis presenta-
tion, whereas anti-Caspr2 can present with encephalitis, peripheral nerve hyperexcitability, or 
Morvan syndrome (2, 3). To our knowledge, there is only one case report of VGKC autoimmune 
encephalitis associated with ischemic stroke (4). In this report, we describe a case of LGI1- and 
VGKC-positive autoimmune encephalitis that preceded a stroke in a young patient with no sig-
nificant vascular risk factors and discuss the possible relationship. This case report was approved 
by our local IRB and exempt from informed consent because all identifying patient information 
was removed.
BaCKGRoUND
A 45-year-old woman with a history of depression and recently diagnosed with hypertension 
presented to our emergency department after several months of progressive neurological symp-
toms. Her symptoms initially began several months before. She described flashing lights in her 
peripheral vision occurring several times daily and was evaluated at another hospital with a brain 
FIGURe 2 | MRI brain FLaIR sequences performed on admission to our hospital (a), 7 days after admission (B), 1 month after discharge (C), and 
4 months after discharge (D). These images demonstrate the evolution of the left mesial temporal lobe lesion during admission and improvement 1 month and 
4 months after discharge.
FIGURe 1 | MRI sequences from admission to the osH 2 days prior to admission at our hospital. These images demonstrate the cerebellar subacute 
infarction with no restricted diffusion, but contrast enhancement. These images remained unchanged 2 days later on admission to our hospital. (a) DWI, (B) T2, 
(C) T1 precontrast, and (D) T1 postcontrast.
2
McGinley et al. LGI1 and Stroke
Frontiers in Neurology | www.frontiersin.org May 2016 | Volume 7 | Article 68
MRI with and without contrast and a 24-h EEG, which were 
both reportedly unremarkable. Her visual symptoms were 
spontaneously resolved but then reoccurred 2  months later. 
Additionally, she developed right facial twitching and abnormal 
movements of her right arm. These episodes gradually increased 
in frequency until they were occurring multiple times daily. She 
was evaluated again at another hospital and empirically placed 
on levetiracetam 500  mg twice daily for presumed seizures. 
Another 24-h EEG at this time was unremarkable. Her episodes 
became more frequent and the intensity of the right upper 
extremity jerking worsened. On the second admission, she had a 
brain MRI with and without contrast that demonstrated several 
new abnormalities (Figures  1 and 2), another unremarkable 
prolonged EEG, and a lumbar puncture. Her cerebral spinal 
fluid demonstrated a protein of 76 (normal range 12–60  mg/
dL), glucose of 62 (normal range 40–70 mg/dL), 1 WBC (normal 
range 0–10/mm3), 2 red blood cells (RBCs) (normal = 0), and 
a negative HSV PCR. Valproic acid was added, and she was 
discharged home.
Two days following discharge, she presented to our emergency 
department with increasing frequency of right facial twitching 
and right upper extremity jerking despite compliance with the 
prescribed levetiracetam and valproic acid. Her husband also 
reported short-term memory impairment. Her neurological 
exam was significant for right hand finger abduction and wrist 
extension weakness along with diffuse hyperreflexia. There 
was no nystagmus, dysmetria, or gait ataxia. A repeat brain 
MRI with and without gadolinium contrast demonstrated a 
wedge-shaped lesion in the left cerebellar hemisphere with 
enhancement and without restricted diffusion. The appear-
ance was consistent with a subacute ischemic infarction that 
was unchanged from the images obtained the week before 
(Figure 1). There was also T2 hyperintensity on fluid attenuation 
inversion recovery (FLAIR) sequences in the left hippocampus, 
which was unchanged when compared to the images obtained 
1 week before (Figure 2). Continuous video EEG captured sev-
eral episodes of impaired consciousness with abnormal right 
face and arm movements, but no electrographic seizures were 
seen. She underwent investigations for both the stroke and 
left hippocampal lesion. Transthoracic and transesophageal 
echocardiograms were both unremarkable. No arrhythmias 
were seen on telemetry during her entire 21-day hospitaliza-
tion. MRA head and neck and CT angiography of the head 
were unremarkable. A hypercoagulable work-up, including 
lupus anticoagulant, cardiolipin antibody, beta2-glycoprotein, 
lipoprotein (a), antithrombin III, protein C, protein S, serum 
FIGURe 3 | FDG pet Ct scan demonstrating increased FDG uptake in 
the medial left temporal lobe corresponding to the area of increased 
FLaIR signal seen on MRI brain.
3
McGinley et al. LGI1 and Stroke
Frontiers in Neurology | www.frontiersin.org May 2016 | Volume 7 | Article 68
homocysteine, fibrinogen, and activated protein C resistance, 
was unremarkable. She underwent two lumbar punctures 
(LP) during her admission at our hospital. The first LP was 
performed 8 days after her previous LP at another hospital and 
had a protein of 25 (normal range 15–45 mg/dL), glucose of 53 
(normal range 45–75 mg/dL), 0 WBC (normal range 0–8/UL), 
and 0 RBC (normal 0/UL). The second LP at our hospital was 
performed 18 days after the initial LP at the previous hospital 
and was significant for protein of 78, glucose of 71, 1 WBC, 
and 11 RBCs. Her clinical picture and left temporal lesion on 
imaging were consistent with limbic encephalitis. CT of the 
chest, abdomen, and pelvis was unremarkable for malignancy. 
A whole body PET scan also demonstrated no evidence of sys-
temic malignancy, but a hypermetabolic area in the left mesial 
temporal lobe in the region of the hyperintensity seen on T2 
FLAIR was present (Figure  3). Ma2, CRMP5, amphiphysin, 
anti Yo, Zic4, anti-Hu, and NMDA antibodies in CSF were neg-
ative. However, CSF anti-LGI1 was present and serum VGKC, 
which was >650 pmol/L (negative <450, borderline 450–650, 
and positive >650 pmol/L), was present. She was empirically 
treated with IV methylprednisolone1000 mg daily for 5 days 
and subsequently given 5  days of IVIG 400  mg/kg/day after 
the antibody results were reported. Maintenance treatment 
with mycophenolate mofetil 250  mg twice daily and an oral 
prednisone taper (50 mg × 3 days, then 40 mg × 3 days, and 
then 30-mg maintenance) was prescribed. Antiepileptic medi-
cations were discontinued. The episodes of adventitial move-
ment and altered sensorium were consistent with faciobrachial 
dystonic seizures well described to occur in association with 
LGI1 autoimmune encephalitis. These seizures often do not 
have an EEG correlation and do not respond to antiepileptic 
drugs. They decreased in frequency throughout the hospital 
course. The right hand weakness improved and was resolved 
by the time of discharge. Her cognitive impairment improved, 
but she had residual difficulty with word recall and short-term 
memory at the time of discharge. Her only identifiable vascular 
risk factor, recently diagnosed hypertension, was treated with 
lisinopril and metoprolol. She was discharged on aspirin 81 mg 
daily. At her outpatient follow-up 1 month and 4 months after 
discharge, she had had no subsequent ischemic events and her 
memory had progressively improved. Repeat imaging 1 month 
and 4 months post-hospitalization showed near complete reso-
lution of the mesial temporal lobe lesion (Figure 2).
DIsCUssIoN
This case illustrates a presentation of a premenopausal woman 
with classic findings of LGI1 subtype of VGKC antibody-
associated autoimmune encephalitis and a recent cryptogenic 
ischemic stroke. To our knowledge, there has been only one 
report of a patient, published by Simal et  al., with autoim-
mune encephalitis associated with stroke (4). He was a man 
in his sixth decade with hypertension, hyperlipidemia, and 
coronary artery disease, who was initially admitted with a 
middle cerebral artery distribution ischemic infarction. He 
developed symptoms of autoimmune encephalitis during his 
stroke admission, and it seemed clear that the stroke preceded 
the autoimmune encephalitis. The authors hypothesized that 
the stroke leads to disruption of the blood brain barrier allow-
ing for easier access of the autoantibodies to the CNS. In our 
case, it is not clear which disease process occurred first. Given 
that the stroke appeared subacute on imaging after months of 
symptoms consistent with autoimmune encephalitis, it is rea-
sonably surmised that the autoimmune encephalitis preceded 
the stroke. If this is the case, could autoimmune encephalitis be 
a risk factor for ischemic stroke? We propose several potential 
explanations.
One possibility is that the systemic inflammation during 
an autoimmune encephalitis leads to a prothrombotic state. 
Previous reports have described depressed levels of circulating 
antithrombotic-activated protein C and elevated levels of C4b-
binding protein. These were primarily young patients with stroke 
and recent infection (5). Autoimmune encephalitis could also 
be associated with or upregulate another antibody that medi-
ates vascular damage. This has been described in the case of 
antiendothelial cell antibodies, which are associated with several 
connective tissue disorders, including systemic lupus erythema-
tous, granulomatosis with polyangiitis, and Susac’s syndrome 
(5–7). Finally, the stroke could have occurred independently 
and potentiated the autoimmune encephalitis. The patient’s 
symptoms were indolent for several months, but when she was 
presented with more florid cognitive decline and increased 
seizures, the ischemic stroke was first visualized. Blood–brain 
barrier injury from the stroke could have allowed easier access 
of antibodies to the CNS, as suggested by Simal et al., resulting 
in worsening of her condition.
Ultimately, the outcomes for these patients are promising. 
Current literature indicates that syndromes associated with 
an antibody against a neural surface antigen as opposed to an 
intracellular or paraneoplastic antigen often respond better to 
immunotherapy (3). The first line therapies for VGKC spectrum 
disorders include steroids, intravenous immunoglobulins, and 
plasma exchange. These treatment modalities can be used 
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alone or in combination (8). If the patient is refractory to these 
 treatments, rituximab or cyclophosphamide has been suggested 
due to their effectiveness in other forms of limbic encephalitis 
(3). A recent systematic review analyzed specific outcomes for 
clinical recovery and MRI findings (9). Neuropsychiatric symp-
toms were often subjectively better, but objective outcomes were 
more variable. MRI findings often have significant improve-
ment, but residual focal atrophy has also been described (8). The 
most significant improvements are reported in patients with a 
non-paraneoplastic etiology, affective predominant symptoms, 
classical radiological findings, and large decreases in antibody 
titers (9).
CoNCLUsIoN
In conclusion, this case is an example of LGI1 autoimmune 
encephalitis associated with ischemic stroke that raises questions 
regarding possible relationships between these entities.
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